Figure 3.
Comparison of the mutational landscape of HGBCL-NOS to DLBCL-NOS and EBV− BL. (A) Oncoplot showing the mutation status of recurrently mutated genes for 61 HGBCL-NOS, 341 DLBCL-NOS, and 63 BL tumors. HGBCL-NOS and BL tumors were sequenced by WGS or WES, and DLBCL-NOS tumors were sequenced using a targeted capture panel covering 125 genes. Genes included in the plot represent the intersection between (1) genes covered by the targeted capture panel and (2) genes that were identified as significantly mutated in HGBCL-NOS, DLBCL-NOS, or BL and mutated at a frequency of ≥10% in at least one of these groups. Nine genes that fulfilled the second criterion were not covered by the capture panel (EBF1, FBXO11, IGLL5, KIAA1671, PCBP1, PHF6, RFX7, SMARCA4, and TFAP4). Genes are ordered by their mutational frequency across all groups, and gene mutation frequencies for each group are shown in the bar plots on the right. (B) Comparison between HGBCL-NOS and BL, with DLBCL shown in faded color for reference. Genes with significantly different mutation frequencies between HGBCL-NOS and BL are displayed. (C) Comparison between HGBCL-NOS and DLBCL, with BL shown in faded color for reference. Genes with significantly different mutation frequencies between HGBCL-NOS and DLBCL are displayed. P values were calculated using the Fisher exact test and adjusted for multiple comparisons using the Benjamini-Hochberg method. ∗Q < 0.1; ∗∗Q < 0.01; ∗∗∗Q < 0.001; ∗∗∗∗Q < 0.0001.

Comparison of the mutational landscape of HGBCL-NOS to DLBCL-NOS and EBV− BL. (A) Oncoplot showing the mutation status of recurrently mutated genes for 61 HGBCL-NOS, 341 DLBCL-NOS, and 63 BL tumors. HGBCL-NOS and BL tumors were sequenced by WGS or WES, and DLBCL-NOS tumors were sequenced using a targeted capture panel covering 125 genes. Genes included in the plot represent the intersection between (1) genes covered by the targeted capture panel and (2) genes that were identified as significantly mutated in HGBCL-NOS, DLBCL-NOS, or BL and mutated at a frequency of ≥10% in at least one of these groups. Nine genes that fulfilled the second criterion were not covered by the capture panel (EBF1, FBXO11, IGLL5, KIAA1671, PCBP1, PHF6, RFX7, SMARCA4, and TFAP4). Genes are ordered by their mutational frequency across all groups, and gene mutation frequencies for each group are shown in the bar plots on the right. (B) Comparison between HGBCL-NOS and BL, with DLBCL shown in faded color for reference. Genes with significantly different mutation frequencies between HGBCL-NOS and BL are displayed. (C) Comparison between HGBCL-NOS and DLBCL, with BL shown in faded color for reference. Genes with significantly different mutation frequencies between HGBCL-NOS and DLBCL are displayed. P values were calculated using the Fisher exact test and adjusted for multiple comparisons using the Benjamini-Hochberg method. ∗Q < 0.1; ∗∗Q < 0.01; ∗∗∗Q < 0.001; ∗∗∗∗Q < 0.0001.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal